Enhanced neonatal immune response using TLR ligands

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		CMCC 1262
IP Type:		Licensable Technology
Title:		Enhanced neonatal immune response using TLR ligands
Inventor:		Wessels, Michael
Summary:		Researchers at Children's Hospital Boston have identified agonists that effectively activate neonatal antigen presenting cells to perform more like mature antigen presenting cells. Following treatment of neonatal mononuclear cells with a class of Toll-like receptor (TLR) agonists, indicators of an effective anti-micribial immune response dramatically increased in monocytes and dendritic cells, including a Th1-like cytokine profile and increased expression of co-stimulatory molecules. Our investigators identified a small group of selective TLR agonists that effectively activated neonatal antigen presenting cells to generate immune responses with similar strength and kinetics to adult cells.
Tech Type:		Therapeutics - Methods \| Therapeutics - Drugs
URL:		http://www.childrensinnovations.org/SearchDetails.aspx?id=1262
Contact:		Abbie Meyer, (617) 919-3011, Abbie.Meyer@childrens.harvard.edu
Organization:		Children's Hospital Boston

Display all intellectual properties for Wessels, Michael
Display all intellectual properties for Children's Hospital Boston